Skip to main content
SpringerLink
Log in

Ivacaftor - the luck of the Irish!

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McKone E. Evidence Supporting Reimbursement for a New Cystic Fibrosis Drug. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : 2 Nov 2013

  2. Barry M. Health Technology Assessment of the New Cystic Fibrosis Drug. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : 2 Nov 2013

  3. Reilly J. Ivacaftor (Kalydeco) - the Healthcare Decision. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : 2 Nov 2013

  4. NHS Commissioning Board. Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis. Internet Document : Mar 2013. Available from: URL: http://www.england.nhs.uk

  5. Scottish Medicines Consortium. SMC advice: budesonide (Budenofalk); budesonide (Budenofalk) Abbreviated; ceftaroline fosamil (Zinforo); clostridium botulinum toxin A (Dysport); dapagliflozin (Forxiga); glycopyrronium (Seebri Breezhaler); ivacaftor (Kalydeco); vildagliptin (Galvus). Internet Document : 14 Jan 2013. Available from: URL: http://www.scottishmedicines.org.uk

  6. Scottish Medicines Consortium. SMC advice: fluocinolone acetonide (Iluvien); ivacaftor (Kalydeco); linaclotide (Constella); pegylated interferon alfa-2a (Pegasys); saxagliptin + metformin (Komboglyze). Internet Document : 10 Jun 2013. Available from: URL: http://www.scottishmedicines.org.uk

  7. Medicines Fund. Media Release : 14 Jan 2013. Available from: URL: http://www.scotland.gov.uk.

  8. Welsh Government. Written Statement - Access to new medicines: availability of ivacaftor (Kalydeco) within NHS Wales for the treatment of cystic fibrosis. Internet Document : 10 May 2013. Available from: URL: http://wales.gov.uk.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ivacaftor - the luck of the Irish!. PharmacoEcon Outcomes News 692, 3–4 (2013). https://doi.org/10.1007/s40274-013-0884-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0884-6

Search

Navigation